NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $1.95 -0.06 (-2.99%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$1.95 0.00 (0.00%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$1.89▼$2.0350-Day Range$1.11▼$2.0552-Week Range$0.65▼$2.16Volume357,814 shsAverage Volume467,879 shsMarket Capitalization$116.82 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingModerate Buy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 47% of companies evaluated by MarketBeat, and ranked 588th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOpus Genetics has a consensus price target of $7.75, representing about 297.4% upside from its current price of $1.95.Amount of Analyst CoverageOpus Genetics has only been the subject of 2 research reports in the past 90 days.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($1.22) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 9.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opus Genetics has recently increased by 39.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.56% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opus Genetics has recently increased by 39.51%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.33 News SentimentOpus Genetics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Opus Genetics this week, compared to 2 articles on an average week.Search Interest19 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.MarketBeat Follows3 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Opus Genetics is held by insiders.Percentage Held by InstitutionsOnly 14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesAnalysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $7.75October 21 at 2:22 AM | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Research Coverage Started at Chardan CapitalOctober 19, 2025 | americanbankingnews.comThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 23 at 2:00 AM | Porter & Company (Ad)Opus Genetics initiated with a Buy at ChardanOctober 16, 2025 | msn.comChardan Capital Initiates Coverage of Opus Genetics (IRD) with Buy RecommendationOctober 16, 2025 | msn.comOpus Genetics to Participate in Chardan's 9th Annual Genetic Medicines ConferenceOctober 14, 2025 | globenewswire.comOpus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025October 2, 2025 | globenewswire.comOpus Genetics, Inc. - Special CallSeptember 30, 2025 | seekingalpha.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $1.19 at the start of the year. Since then, IRD shares have increased by 63.9% and is now trading at $1.95. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) issued its quarterly earnings data on Friday, May, 7th. The company reported ($0.47) EPS for the quarter. Opus Genetics had a negative net margin of 377.89% and a negative trailing twelve-month return on equity of 384.33%. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2021Today10/23/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Price Target for Opus Genetics$7.75 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+297.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.53 million Net Margins-377.89% Pretax Margin-377.89% Return on Equity-384.33% Return on Assets-148.90% Debt Debt-to-Equity Ratio0.06 Current Ratio1.90 Quick Ratio1.90 Sales & Book Value Annual Sales$10.99 million Price / Sales10.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book9.29Miscellaneous Outstanding Shares59,910,000Free Float55,954,000Market Cap$116.82 million OptionableN/A Beta0.11 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IRD) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
